Please wait ...

It's the most compelling topic in psychotherapy today… and one of the biggest breakthroughs our field has ever seen!

With medicinal psychedelic substances becoming more available throughout the country, Psychedelic-Assisted Psychotherapy (PAP) is poised to change the landscape of therapy as we know it.

Many clients are already asking their therapists about psychedelics, and some are even exploring them on their own.

So, whether you choose to directly incorporate PAP into your practice or not, it's critical that you know enough about this topic to guide your clients in integrating psychedelic-assisted experiences in their daily lives.

That's why we're partnering with the faculty at Fluence, one of the leading organizations for Psychedelic-Assisted Psychotherapy training and research…

to offer this exclusive online course that provides in-depth insight into the most common medicinal psychedelic substances (including MDMA, Ketamine, Ayahuasca, and more)in simple, easy-to-comprehend language, so you'll know exactly how to speak to your clients about this topic.

You'll also hear from therapy leaders Dick Schwartz, Gabor Maté, and others as they share their unique, personal perspectives on what we as therapists need to know to effectively work in this developing therapeutic area.
Psychotherapy Networker's
Psychedelics in Therapy
MDMA, Psilocybin, Ketamine, Micro-Dosing, & More

$699.90 Value
Just $149.00 (GST Inclusive) Today — Unbelievable Savings!
 
Plus, earn up to 11.5 CPD Hours included in the course tuition.
Click here for course objectives and outline
What You'll Learn

This training is uniquely designed to provide the skills and insight so you'll:
  • Know exactly how to talk to clients about psychedelics and their use for PTSD and other mental health concerns
  • Get the most up-to-date training on each of the most widely used substances including MDMA, Ketamine, Psilocybin, and Ayahuasca
  • Be able to help clients TODAY who are using or micro-dosing on their own
  • Know the best paths to go forward if you want to become more involved in psychedelic-assisted therapies

Psychedelics in Therapy Training Outline:
Elizabeth Nielson, PhD
Psychedelic Harm Reduction and Integration in Clinical Practice

What do you do when a client lets you know they’re going to use psychedelics on their own? Is there anything you can do to help reduce harm? And what about micro-dosing, which is gaining popularity? This presentation will provide essential information and guidance on how to have these important conversations — including discussions about microdosing, responding to requests for referrals to non-licensed providers, and working with difficult experiences.

Matthew Johnson, PhD
Evidence-Based Therapy Practices in Psilocybin-Assisted Interventions

This workshop will explore modern approaches to psychotherapy using the classic psychedelic compound, psilocybin. This includes a variety of disorders such as substance use, affective, and anxiety disorders. Methods for assuring safety as well as maximizing efficacy will be covered.

Ingmar Gorman, PhD
MDMA-Assisted Therapy in the Treatment of Post-traumatic Stress Disorder

Early trial studies show that MDMA has incredible potential to treat PTSD and can even eliminate the diagnosis altogether! With a second trial study nearing completion and the possibility of MDMA becoming an available treatment in the near future, now is your opportunity to get a full and up-to-date understanding of MDMA-assisted psychotherapy for your practice.

Seema Desai, MD
New Models for Ketamine-Assisted Psychotherapy

Ketamine is an FDA-approved medication that has been used for anaesthesia and pain relief in adults and children for many years. However, it has also been researched and used for the treatment of depression, post-traumatic stress disorder, and other "treatment resistant" mental health disorders — with promising results. As Ketamine-Assisted Psychotherapy gets closer to becoming available for mental health therapists, this is your opportunity to get the latest insights on this developing healing opportunity.

Jeffrey Guss, MD
An Introduction to Ayahuasca for Mental Health Providers

Ayahuasca is one of the most popular and least understood psychedelic agents. In this talk, we'll cover an introduction to ayahuasca, including biochemical, neuroscientific, and historical/cultural aspects of its use. Following this, we'll cover contemporary research on its effects on mental health and its use for the treatment of conditions such as addiction and depression. Lastly, some of the psychodynamic aspects of shamanic and syncretic religious settings will be described.

Gabor Maté, MD
When Psychedelics Hurt: Unpleasant Psychedelic Experiences as a Pathway to Healing

Not all experiences with psychedelics feel good. In fact, it's common for people to experience some level of distress, and without proper guidance, these unpleasant journeys can leave people feeling less integrated than they were before. In this dynamic conversation, Gabor Maté, MD, will present from research and his own extensive experience, ways to reduce the likelihood of harm from psychedelic use, and how unpleasant experiences can be transformed into deeply meaningful and healing experiences.

Victor Cabral, MSW, LSW
Psychedelic-Assisted Psychotherapies: A Policy Perspective

In anticipation of FDA approval and medicalization, clinicians everywhere are eager to learn more about Psychedelic-Assisted Psychotherapy. But many questions remain unanswered around the current policy landscape and the changes needed to welcome these medicines into our current healthcare system and in psychotherapy. This presentation will provide you with an overview of the history and current state of psychedelic policy and look ahead to what the future holds for clinicians like you to practice psychedelic-assisted therapy.

Phil Wolfson, MD
The Fantastic Effects of Ketamine Assisted Psychotherapy: A Revolution in Clinical Practice

Ketamine has been used legally for depression, anxiety, and a host of other mental health conditions. This presentation reviews the key elements of integration strategies specific to the mental health condition being addressed. There are specific nuances of Ketamine treatment that will be outlined and compared to other psychedelics.

Monnica T. Williams, PhD
Psychedelics & Racial Justice

Psychedelics have been studied for the treatment of PTSD, depression, end-of-life anxiety, OCD, addictions, and a number of other mental health conditions. However, research studies of psychedelic psychotherapies have largely excluded people of colour, leaving important questions unaddressed for these populations. Dr. Williams will review relevant research, documenting exclusion based on the international literature. She will discuss ethnic minority mental health and how psychedelic therapies may help or hinder healing for people of colour. Also discussed are the next steps in ensuring that access to culturally-informed care is prioritized as several psychedelics move into late-phase trials and expanded access, including the importance of culturally-informed approaches and training focused on therapy providers of colour.

Dick Schwartz, PhD
The Internal Family Systems Approach to Psychedelic Experiences

The psyche is a delicate ecosystem and psychedelics are powerful agents that can profoundly affect it. While that effect can be positive, there is also the potential for extreme disruption. That's where Internal Family Systems (IFS) can help therapists and clients alike maintain a steady presence and not overreact to sometimes dramatic shifts. In this talk, IFS founder Dick Schwartz will address the probable risks and benefits of incorporating psychedelics in the therapy room.
Psychotherapy Networker's
Psychedelics in Therapy
MDMA, Psilocybin, Ketamine, Micro-Dosing, & More

$699.90 Value
Just $149.00 (GST Inclusive) Today — Unbelievable Savings!
 
Plus, earn up to 11.5 CPD Hours included in the course tuition.
Click here for course objectives and outline
Meet Your Course Experts
Richard Schwartz, PhD, is the founder of the Internal Family Systems (IFS) therapy model. He now serves on the Faculty of the Department of Psychiatry at Harvard Medical School and is a Senior Fellow at the Meadows treatment centre in Arizona. In 2000, he founded the Center for Self Leadership (now IFS Institute), which offers three levels of training and workshops in IFS for professionals and the general public, both in this U.S. and abroad. A featured speaker for national professional organizations, Dr. Schwartz has published many books and over fifty articles about IFS.

Click here for information about Richard C. Schwartz
Richard Schwartz, PhD

Gabor Maté, MD, is a renowned speaker and bestselling author. He is highly sought after for his expertise on a range of topics including trauma treatment, addiction, stress, and childhood development. As an author, Dr. Maté has written several bestselling books including the award-winning In the Realm of Hungry Ghosts: Close Encounters with Addiction; When the Body Says No; The Cost of Hidden Stress; and Scattered Minds: A New Look at the Origins and Healing of Attention Deficit Disorder, as well as the newly released The Myth of Normal.

Click here for information about Gabor Maté
Gabor Maté, MD

Dr. Elizabeth Nielson is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders.

Click here for information about Elizabeth Nielson
Dr. Elizabeth Nielson

Dr. Ingmar Gorman is a co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. As a psychologist, he shares his expertise in empirically supported psychedelic treatments with his clients and trainees alike.

Click here for information about Ingmar Gorman
Dr. Ingmar Gorman

Seema Desai, MD, is a board-certified child, adolescent, and adult psychiatrist with a clinical interest in the intersection of spirituality and psychiatry. She is currently a study therapist in a MAPS trial examining the effects of MDMA for the treatment of PTSD. She offers psychopharmacology treatment and ketamine-assisted psychotherapy in her private practice.

Click here for information about Seema Desai
Seema Desai, MD

Jeffrey Guss, MD, is a psychiatrist, psychoanalyst, and researcher with specializations in psychoanalytic therapy, addictions, and psychedelic therapy. He was Co-Principal Investigator and Director of Psychedelic Therapy Training for the NYU School of Medicine's study on psilocybin-assisted psychotherapy in the treatment of cancer-related existential distress, and is currently a study therapist on studies of Psilocybin-Assisted treatment of Major Depressive Disorder and MDMA-Assisted Psychotherapy for PTSD.

Click here for information about Jeffrey Guss
Jeffrey Guss, MD

Matthew Johnson, PhD, is The Susan Hill Ward Endowed Professor of Psychedelics and Consciousness Research at Johns Hopkins. Working with psychedelics since 2004, he is one of the world's most widely published experts on psychedelics. He has published research on psychedelics and mystical experiences, personality change, tobacco smoking cessation, cancer distress treatment, and depression treatment. In 2021 he received, as principal investigator, the first grant in 50 years from the US government for a treatment study with a classic psychedelic, specifically psilocybin in the treatment of tobacco addiction. He is also known for his expertise in behavioural economics, addiction, sexual risk behaviour, and research with a wide variety of drug classes.

Click here for information about Matthew W. Johnson
Matthew Johnson, PhD

Victor Cabral, MSW, LSW, CCTP-I, is the Founder of Dreamers of the Day LLC. and serves as the Director of Policy and Regulatory Affairs for Fluence International Inc., a company that provides evidence-based training in psychedelic therapy and integration services to clinicians across the globe.

Click here for information about Victor Cabral
Victor Cabral, MSW, LSW, CCTP-I

Phil Wolfson, MD, is president and CEO of the non-profit Ketamine Research Foundation and directs the training of KAP practitioners through The Ketamine Training Center. Phil's book, The Ketamine Papers, is the seminal work in the burgeoning ketamine arena. He is principal investigator for the MAPS-sponsored Phase 2, the FDA-approved 18-person study of MDMA-Assisted Psychotherapy for individuals with significant anxiety due to life-threatening illnesses. His clinical practice with ketamine has informed his leadership role in the development of Ketamine-Assisted Psychotherapy.

Click here for information about Phil Wolfson

Monnica T. Williams, PhD, is a board-certified licensed clinical psychologist who was named one of the top 25 thought leaders in PTSD by PTSD Journal. Her work has been featured in several major media outlets, including NPR, Huffington Post, CNN, and the New York Times. Dr. Williams has published over 100 book chapters and peer-reviewed articles focused on trauma and other anxiety-related disorders and cultural differences. She is currently an Associate Professor at the University of Ottawa in the School of Psychology, where she is the Canada Research Chair for Mental Health Disparities. She is also Clinical Director of the Behavioral Wellness Clinic in Connecticut, where she provides supervision and training to clinicians for empirically-supported treatments.

Click here for information about Monnica T. Williams
Monnica T. Williams, PhD

Frequently Asked Questions

Yes! Even if you won't go further and practice psychedelic-assisted therapies, we all need to understand this rapidly growing area of therapy. Clients are asking us about it, they are using psychedelics on their own, and many clients will come to your practice having been to ketamine clinics or other psychedelic therapies. Plus, your clients will need help navigating this world of therapies safely, and they need you to help them better understand the risks and benefits as they look to integrate these experiences.

Even if you're not a PAP therapist — you can help! This Online Course is designed for you!

Psychotherapy Networker is a non-profit educational organization. For over 46 years, we have featured the leading researchers, innovators, and developers in the field through our award-winning magazine, CPD trainings, and our annual Symposium.

Our focus is on telling the stories of psychotherapy and being a place where clinicians of all licenses and backgrounds, who practice psychotherapy, can keep up on what's happening in the field, hear captivating stories from colleagues on what's really happening in their practices, learn through CPD trainings from the best in the field, and enjoy the most celebrated annual gathering of psychotherapists in the world each year in March in Washington, D.C.!

Yes! We designed it so you'll get at least 1 hour on EVERY major psychedelic agent being used today — PLUS workshops on integration (after a psychedelic experience) and harm reduction (when clients use on their own or outside of a licensed clinic) — as well as regulations, risks and benefits, ethics, and more!

No — psychedelic-assisted therapies are here NOW. Ketamine clinics are all over the US. Psilocybin is used more widely. People are going on Ayahuasca trips, and many clients are obtaining these substances on their own and using them, sometimes without supervision. Right now, licensed mental health professionals can engage in harm reduction practices (for when clients use outside of a licensed clinic) and in integration (helping clients integrate psychedelic experiences) and provide needed accurate information about risks and benefits.

This online course is designed for exactly that — practical guidance not just for the future, but right here, right now.
 
100% Satisfaction Guarantee
Register for this intensive training course without risk. If you're not completely satisfied, email us at info@pesi.com.au.

We’re that confident you'll find this learning experience to be all that's promised and more than you expected.
 
Psychotherapy Networker's
Psychedelics in Therapy
MDMA, Psilocybin, Ketamine, Micro-Dosing, & More

$699.90 Value
Just $149.00 (GST Inclusive) Today — Unbelievable Savings!
 
Plus, earn up to 11.5 CPD Hours included in the course tuition.
Click here for course objectives and outline

NOTE: No additional discounts or coupons may be applied to this course.
NRS001612 • © PESI AU  •  All rights reserved  •  Email: info@pesi.com.au  •  Phone: 1300 887 622
Back to Top